Overview

• Medical technology firm's Q4 revenue rose 12%, beating analyst expectations

• Adjusted EPS for Q4 was $1.65

• Company repurchased $50 mln in shares during Q4

Outlook

• Company revises 2026 revenue outlook to $950 mln-$1 bln, reflecting 4%-10% growth

• Inspire expects 2026 adjusted operating margin between 6% and 8%

• Company anticipates 2026 adjusted EPS between $1.85 and $2.35

Result Drivers

• INSPIRE V SYSTEM - Revenue growth driven by increased sales volume and favorable sales mix of Inspire V system

• MARKETING INVESTMENTS - Operating expenses increased due to higher investments in patient marketing and education

• REIMBURSEMENT CLARITY - Company received clarification on coding for Inspire V procedure, impacting reimbursement strategy

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$269.10 mln	$265.67 mln (17 Analysts)
Q4 EPS		$4.66
Q4 Net Income		$136.10 mln
Q4 Revenue Growth		12.00%

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Inspire Medical Systems Inc is $130.00, about 90.8% above its February 10 closing price of $68.14

• The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 51 three months ago

Press Release: ID:nGNX16bbtg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.